EAGLE European Post Market Study

Overview

Prospective, multi-center, non-randomized, historical controlled, post-market study of patients requiring surgical repair of a focal articular cartilage lesion or osteochondral defect in the knee.

Full Title of Study: “Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions (“EAGLE”) European Post Market Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2019

Detailed Description

BioMatrix CRD is a CE marked device that is intended to repair focal articular cartilage lesions or osteochondral defects in the knee. BioMatrix CRD™ is a sterile, biphasic, bioresorbable scaffold designed to aid in the repair of cartilage and subchondral bone. The device serves as a scaffold for cellular and extracellular matrix ingrowth supporting the regeneration of cartilage and subchondral bone. The purpose of this post-market study is to confirm the safety and performance of the BioMatrix CRD for its intended use. Fifty (50) patients will be enrolled at up to 10 hospitals in Europe. Patients will be followed for 2 years post-operative to examine the rate of adverse events associated with the device, track improvement in knee pain and knee function over time, and assess the quality of repair tissue.

Interventions

  • Device: BioMatrix CRD

Arms, Groups and Cohorts

  • BioMatrix CRD
    • All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.

Clinical Trial Outcome Measures

Primary Measures

  • Rate of Implant Failure
    • Time Frame: 24 months
    • Rate of implant failure resulting in device removal and/or further surgical intervention due to a device related complication

Secondary Measures

  • Knee Related Adverse Events
    • Time Frame: 24 months
  • Quality of repair tissue as assessed by magnetic resonance imaging
    • Time Frame: at 24 months
  • Improvement in knee pain and function as reported by patients on the Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire
    • Time Frame: 24 months

Participating in This Clinical Trial

Inclusion Criteria

  • Pre-procedure KOOS Pain subscale score less than or equal to 70. – ICRS grade 3 or 4 focal articular cartilage lesion on the medial femoral condyle, lateral femoral condyle or trochlea, which measures less than or equal to15mm in diameter. – Cartilage lesion is amenable to treatment with a single BioMatrix CRD or an osteochondral autograft. Exclusion Criteria:

  • Previous cartilage repair procedure (i.e., microfracture, OATS, ACI) at the intended implantation site. – Clinically significant (> 5 degrees) varus or valgus malalignment in either knee. – Osteoarthritis in the injured knee. – Inflammatory arthropathy – Osteomyelitis or other active infection in either lower limb. – Cortisone or hyaluronic acid knee injections in the past 3 months – Body mass index greater than 35.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kensey Nash Corporation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Justus Gille, PD Dr med, Principal Investigator, University Hopsital Schleswig Holstein Campus Lübeck

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.